Author:
Verloh Niklas,Utpatel Kirsten,Haimerl Michael,Zeman Florian,Fellner Claudia,Fichtner-Feigl Stefan,Teufel Andreas,Stroszczynski Christian,Evert Matthias,Wiggermann Philipp
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Bluemke, D. A. et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 237, 89–98, 10.1148/radiol.2371031842 (2005).
2. Kobayashi, S. et al. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine-pentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. European journal of radiology 81, 3002–3009, 10.1016/j.ejrad.2012.03.029 (2012).
3. Weinmann, H. J. et al. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine/Society of Magnetic Resonance in Medicine 22, 233–237 (1991).
4. Van Beers, B. E., Pastor, C. M. & Hussain, H. K. Primovist, Eovist: what to expect? Journal of hepatology 57, 421–429, 10.1016/j.jhep.2012.01.031 (2012).
5. Van Montfoort, J. E. et al. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. The Journal of pharmacology and experimental therapeutics 290, 153–157 (1999).
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献